CBD reduced pain sensitivity in a mouse model of Parkinson's disease
CBD reversed the increased pain sensitivity caused by experimental parkinsonism in mice, with effects involving CB1 and TRPV1 receptors and potentially mediated through increased anandamide levels.
Quick Facts
What This Study Found
The Parkinson's model (6-OHDA) decreased thermal and mechanical pain thresholds. Both acute and chronic CBD treatment reversed this hyperalgesia and allodynia. CBD's pain-relieving effect was potentiated by a FAAH inhibitor and TRPV1 antagonist, and blocked by CB1/CB2 inverse agonist, suggesting CBD increases endogenous anandamide levels.
Key Numbers
6-OHDA model decreased both thermal and mechanical nociceptive thresholds. Acute and chronic CBD reversed both hyperalgesia and allodynia. FAAH inhibitor and TRPV1 antagonist potentiated CBD; CB1/CB2 inverse agonist blocked it.
How They Did This
Mouse model of Parkinson's (6-hydroxydopamine lesion). CBD administered acutely or chronically. Co-administration studies with FAAH inhibitor, TRPV1 antagonist, and CB1/CB2 inverse agonist to elucidate mechanisms.
Why This Research Matters
Pain is a prevalent but undertreated non-motor symptom of Parkinson's disease. CBD could offer a targeted approach if its mechanisms in this context are understood.
The Bigger Picture
Pain affects the majority of Parkinson's patients but has no specific pharmacotherapy. CBD's ability to restore normal pain sensitivity in this model identifies it as a candidate for further development.
What This Study Doesn't Tell Us
Mouse model; 6-OHDA is a toxic model that does not fully recapitulate human Parkinson's; CBD doses used may not translate directly to human dosing; mechanism studies used pharmacological tools with potential off-target effects.
Questions This Raises
- ?Would CBD reduce pain in Parkinson's patients?
- ?Does the anandamide-mediated mechanism suggest FAAH inhibitors could complement CBD for PD pain?
Trust & Context
- Key Stat:
- Both acute and chronic CBD reversed Parkinson's-related pain hypersensitivity in mice
- Evidence Grade:
- Single animal study with mechanistic dissection; 6-OHDA model has limitations for translating to human PD.
- Study Age:
- Published in 2020.
- Original Title:
- Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease.
- Published In:
- Neuropharmacology, 163, 107808 (2020)
- Authors:
- Crivelaro do Nascimento, Glauce, Ferrari, Daniele Pereira, Guimaraes, Francisco Silveira(2), Del Bel, Elaine Aparecida, Bortolanza, Mariza, Ferreira-Junior, Nilson Carlos
- Database ID:
- RTHC-02485
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Can CBD help with Parkinson's pain?
In this mouse model, CBD effectively reversed the increased pain sensitivity caused by experimental parkinsonism. However, animal model results do not always translate to humans, and clinical trials in Parkinson's patients would be needed.
How does CBD reduce pain in this model?
The researchers found CBD's pain-relieving effect involved CB1 receptors and TRPV1 channels, and was enhanced by blocking the enzyme that breaks down anandamide (an endocannabinoid). This suggests CBD may work partly by boosting the body's own endocannabinoid system.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-02485APA
Crivelaro do Nascimento, Glauce; Ferrari, Daniele Pereira; Guimaraes, Francisco Silveira; Del Bel, Elaine Aparecida; Bortolanza, Mariza; Ferreira-Junior, Nilson Carlos. (2020). Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease.. Neuropharmacology, 163, 107808. https://doi.org/10.1016/j.neuropharm.2019.107808
MLA
Crivelaro do Nascimento, Glauce, et al. "Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease.." Neuropharmacology, 2020. https://doi.org/10.1016/j.neuropharm.2019.107808
RethinkTHC
RethinkTHC Research Database. "Cannabidiol increases the nociceptive threshold in a preclin..." RTHC-02485. Retrieved from https://rethinkthc.com/research/crivelaro-2020-cannabidiol-increases-the-nociceptive
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.